Molecular models of benzene leukemogenesis

Journal of Toxicology and Environmental Health - Part A

Volumn 61, Issue 5-6, 2000, Pages 391-397

  Irons, Richard D ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BENZENE; CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHEMICAL CARCINOGENESIS; CHROMOSOME ABERRATION; CLONE; CONFERENCE PAPER; DNA BINDING; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; LONG TERM EXPOSURE; MOLECULAR MODEL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; BENZENE; CARCINOGENS; HUMANS; LEUKEMIA, MYELOID; MODELS, GENETIC; MYELODYSPLASTIC SYNDROMES;

EID: 0033783652     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/00984100050166415     Document Type: Article

References (52)

1. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., and Su ltan, C. 1982. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:189-199.
2. Bitter, M. A., Le Beau, M. M., Rowley, J. D., Larson, R. A., Golomb, H. M., and Vardiman, J. W. 1987. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum. Pathol. 18:211-225.
3. Bloomfield, C. D., Goldman, A., Hossfeld, D., and de la Chapelle, A. 1984. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet. Cytogenet. 11: 332-350.
4. Cronkite, E. P., Drew, R. T., Inoue, T., Hirabayashi, Y., and Bullis, J. E. 1989. Hematotoxicity and carcinogenicity of inhaled benzene. Environ. Health Perspect. 82:97-108.
5. Cuneo, A., Fagioli, F., Pazzi, I., Talla rico, A., Previati, R., Piva, N., Carli, G. M., Balboni, M., and Castoldi, G. 1992. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. Leuk. Res. 16:789-796.
6. Dempster, A. M., and Snyder, C. A. 1990. Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. Arch. Toxicol. 64:539-544.
7. Fagioli, F., Cuneo, A., Piva, N., Carli, M. G., Previati, R., Balboni, M., Tomasi, P., Cariani, D., Scapoli, G., and Castoldi, G. 1992. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer 70: 77-85.
8. Farris, G. M., Everitt, J. I., Irons, R. D., and Popp, J. A. 1993. Carcinogenicity of inhaled benzene in CBA mice. Fundam. Appl. Toxicol. 20:503-507.
9. Fialkow, P. J., Singer, J. W., Adamson, J. W., Berkow, R. L., Friedman, J. M., Jacobson, R. J., and Moohr, J. W. 1979. Acute nonlymphocytic leukemia: Expression in cells restricted to granulocytic and monocytic differentiation. N. Engl. J. Med. 301:1-5.
10. Foon, K. A., Champlin, R. E., and Gale, R. P. 1990. Acute myelogenous l eukemia and the myelodys-plastic syndromes. In Cancer treatment, ed. C. M. Haskell, pp. 589-606. Philadelphia: W. B. Saunders.
11. Fourth International Workshop on Chromosomes in Leukemia, 1. 1984. The correlation of karyotype and occupational exposure to potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 11:326-331.
12. Golomb, H. M., Alimena, G., Rowley, J. D., Vardiman, J. W., Testa, J. R., and Sovik, C. 1982. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 60:404-411.
13. Gross, S., Gruntmeir, J., Stillman, W., and Irons, R. D. 1996. Hydroquinone alters differentiation of human CD34+ cells in liquid culture. Exp. Hematol. 24:1027.
14. Gross, S., Gruntmeir, J., Helm, K., Stillman, W. S., and Irons, R. D. 1997a. The benzene metabolite, Hydroquinone, alters phenotypic expression of human CD34+ cells in liquid culture. Toxicologist 36:163.
15. Gross, S., Helm, K., Gruntmeir, J., Stillman, W., and Irons, R.D. 1997b. Characterization and phenotypic analysis of differentiating CD34+ human bone marrow cells in liquid culture. Eur. J. Haematol. 59:318-326.
16. Gross, S., Pyatt, D. W., Yang, Y., Stillman, W. S., and Irons, R. D. 1998. Hydroquinone alters DNA binding activity of the transcription factor PU.1in human CD34+ hematopoietic progenitor cells. Toxicologist 42:269.
17. Holden, J. T., Geller, R. B., Farhi, D. C., Holland, H. K., Stempora, L. L., Phillips, C. N., and Bray, R. A. 1995. Characterization of Thy-1(CDw90) expression in CD34+ acute leukemia. Blood 86: 60-65.
18. Irons, R. D. 1997. Effects of the benzene metabolite, hydroquinone, on regulation of differentiation and proliferation of human hematopoietic stem and progenitor cells in vitro. Toxicologist 36: 105-106.
19. Irons, R. D., and Stillman, W. S. 1993. Cell proliferation and differentiation in chemical l eukemogene-sis. Stem Cells 11:235-242.
20. Irons, R. D., and Stillman, W. S. 1996a. Impact of benzene metabolites on differentiation of bone marrow progenitor cells. Environ. Health Perspect. Suppl. 104:1247-1253.
21. Irons, R. D., and Stillman, W. S. 1996b. The effects of benzene and other leukaemogenic agents on haematopoietic stem and progenitor cell differentiation. Eur. J. Haematol. Suppl. 57:119-124.
22. Irons, R. D., and Stillman, W. S. 1996c. The process of leukemogenesis. Environ. Health Perspect. Suppl. 104:1239-1246.
23. Irons, R. D., Stillman, W. S., Colagiovanni, D. B., and Henry, V. A. 1992. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proc. Natl. Acad. Sci. USA 89:3691-3695.
24. Johansson, B., Mertens, F., Heim, S., Kristoffersson, U., and Mitelman, F. 1991. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic l eukemia (sANLL). Eur. J. Haematol. 47: 17-27.
25. Kroef, M. J. P. L., Fibbe, W. E., Mout, R., Jansen, R. P. M., Haak, H. L., Wessels, J. W., Van Kamp, H., Willemze, R., and Landegent, J. E. 1993. Myeloid but not lymphoid cells carry the 5q deletion: Polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 81:1849-1854.
26. Larson, R. A., Le Beau, M. M., Vardiman, J. W., and Rowley, J. D. 1996. Myeloid leukemia after hematotoxins. Environ. Health Perspect. Suppl. 104:1303-1307.
27. Le Beau, M. M., Albain, K. S., Larson, R. A., Vardiman, J. W., Davis, E. M., Blough, R. R., Golomb, H. M., and Rowley, J. D. 1986. Clinical and cytogenetic correlations in 63patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol. 4:325-345.
28. Mijovic, A., and Mufti, G. J. 1998. The myelodysplastic syndromes: Towards a functional classification. Blood Rev. 12:73-83.
29. Mitelman, F., Brandt, L., and Nilsson, P. G. 1978. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic l eukemia. Blood 52:1229-1237.
30. Mitelman, F., Nilsson, P. G., Brandt, L., Alimena, G., Gastaldi, R., and Dallapiccola, B. 1981. Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 4:197-214.
31. Mufti, G. J. 1992. Chromosomal deletions in the myelodysplastic syndrome. Leuk. Res. 16:35-41.
32. Nagarajan, L., Lange, B., Cannizzaro, L., Finan, J., Nowell, P. C., and Huebner, K. 1990. Molecular anatomy of a 5q interstitial deletion. Blood 75:82-87.
33. Narod, S. A., and Dube, I. D. 1989. Occupational history and involvement of chromosomes 5 and 7 in acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 38:261-269.
34. Noel, P., Tefferi, A., Pierre, R. V., Jenkins, R. B., and Dewald, G. W. 1993. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 7:10-18.
35. Ohyashiki, K., Ohyashiki, J. H., Iwabuchi, A., and Toyama, K. 1996. Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Leuk. Lymphoma23:406-415.
36. Orazi, A., Cattoretti, G., Soligo, D., Luksch, R., and Lambertenghi-Deliliers, G. 1993. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology of the prognostic assessment. Leukemia 7:838-847.
37. Pedersen-Bjergaard, J., Philip, P., Mortensen, B. T., Ersboll, J., Jensen, G., Panduro, J., and Thomsen, M. 1981. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood 57:712-723.
38. Pedersen-Bjergaard, J., Philip, P., Perdersen, N. T., Hou-Jensen, K., Svejgaard, A., Jensen, G., and Nissen, N. I. 1984. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Cancer 54:452-462.
39. Pedersen-Bjergaard, J., Pedersen, M., Roulston, D., and Philip, P. 1995. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid l eukemia. Blood 86:3542-3552.
40. Rowley, J. D., Golomb, H. M., and Vardiman, J. 1977. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin l ym-phomas. Blood 50:759-770.
41. Rowley, J. D., Golomb, H. M., and Vardiman, J. W. 1981. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58:759-767.
42. Sawada, K., Sato, N., Notoya, A., Tarumi, T., Hirayama, S., Takano, H., Koizumi, K., Yasukouchi, T., Yamaguchi, M., and Koike, T. 1995. Proliferation and differentiation of myelodysplastic CD34+ cells: Phenotypic subpopulations of marrow CD34+ cells. Blood 85:194-202.
43. Stillman, W. S., Varella-Garcia, M., Gruntmeir, J. J., and Irons, R. D. 1997. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line. Leukemia 11:1540-1545.
44. Stillman, W. S., Varella-Garcia, M., and Irons, R. D. 1999. The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and-5q31in a human cell line. Leuk. Lymphoma 35:269-281.
45. Stillman, W. S., Varella-Garcia, M., and Irons, R. D. 2000. The benzene metabolite, hydroquinone, selectively induces 5q31-and-7 in human CD34+CD19-bone marrow cells. Exp. Hematol. 28:169-176.
46. Van den Berghe, H., Cassiman, J. J., David, G., Fryns, J. P., Michaux, J. L., and Sokal, G. 1974. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251: 437-438.
47. Varmus, H., and Weinberg, R. A. 1993. Genes and the biology of cancer. New York: Scientific American Library.
48. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319:525-532.
49. Willman, C. L., and Whittaker, M. H. 1990. The molecular biology of acute myeloid l eukemia. Protooncogene expression and function in normal and neoplastic myeloid cells. Clin. Lab. Med. 10:769-796.
50. Young, K. M. 1985. Myeloproliferative disorders. Vet. Clin. North Am. Small Anim. Pract. 15:769-781.
51. Zhang, L. P., Rothman, N., Wang, Y. X., Hayes, R. B., Li, G. L., Dosemeci, M., Yin, S. N., Kolachana, P., Titenko-Holland, N., and Smith, M. T. 1998a. Increased aneusomy and long arm deletion of chromosomes 5 and 7 in the lymphocytes of Chinese workers exposed to benzene. Carcinogenesis 19:1955-1961.
52. Zhang, L. P., Wang, Y. X., Shang, N., and Smith, M. T. 1998b. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes. Leuk. Res. 22:105-113.